# US 2021/0330761 A1 · Plasminogen treatment of conditions associated with pai-1 overexpression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330761 A1
- Document ID: US20210330761A1
- Status: Published application
- Kind: A1
- Application number: 16/625,335
- Filed: 2018-06-22
- Published: 2021-10-28
- Earliest claimed: 2017-06-23
- Assignees: Prometic Biotherapeutics, Inc.
- Applicants: Prometic Biotherapeutics, Inc.
- Inventors: LYNE GAGNON; BRIGITTE GROUIX; PIERRE LAURIN
- Web page: https://patentgrep.com/patent/US20210330761A1

## CPC

- A61K 38/484: {Plasmin (3.4.21.7)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level. The conditions and diseases that are characterized with an increased PAI-1 level, are regrouped within two categories: the diseases associated with an impaired vascular or tissue remodeling capacity, and the metabolic and hormonal disorders associated with an increased PAI-1 level.

## Claims

### Claim 1

A method for preventing, slowing progression of, or treating, a disease or a condition in a subject, whererein said disease or condition is associated with an overexpression of PAI-1, wherein the method comprises the administration of plasminogen, a variant thereof or an analog thereof to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PAI-1 overexpression occurs in blood or in an injured tissue of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is a non-plasminogen-deficient subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the subject has a plasmatic plasminogen activity that is greater than 70% of a normal plasminogen activity level.

### Claim 5 (depends on 1)

The method of claim 1, wherein said disease or a condition associated with an overexpression of PAI-1 is a disease associated with an impaired vascular or tissue remodeling capacity, or a metabolic or hormonal disorder.

### Claim 6 (depends on 5)

The method of claim 5, wherein the disease associated with an impaired vascular or tissue remodeling capacity is chronic renal disease, glomerulosclerosis, fibrosis, tubulointerstitial fibrosis, glomerulonephritis, atherosclerosis, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, chronic kidney disease (CKD), membranous nephropathy, or chronic allograft nephropathy.

### Claim 7 (depends on 5)

The method of claim 5, wherein the metabolic or hormonal disorder is obesity, polycystic ovarian disease, amyloidosis, Alzheimer's disease, alopecia, or aging.

### Claim 8 (depends on 6)

The method of claim 6, wherein the disease is a pulmonary fibrosis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.

### Claim 10 (depends on 8)

The method of claim 8, wherein plasminogen, a variant thereof or an analog thereof, is used in combination with an antifibrotic agent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the antifibrotic agent is pirfenidone.

### Claim at position 12

12-15. (canceled)

### Claim 16

A method for down-regulating a PAI-1 overexpression in an injured tissue of a subject, wherein said method comprises the administration of plasminogen, a variant thereof or an analog thereof to the subject.
